Pricing Log in Create free account

ImmunityBio, Inc. (IBRX) vs Summit Therapeutics PLC (SMMT)

ImmunityBio, Inc. and Summit Therapeutics PLC are both Biotechnology companies. Summit Therapeutics PLC is the larger, with a market value of $12.3B against $10.6B — 1.2× the size. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against −61.0%. Summit Therapeutics PLC has the higher net margin (0.00% vs −598.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, ImmunityBio, Inc. leads on 9 and Summit Therapeutics PLC on 7.

Valuation

Metric IBRX SMMT Biotechnology median
P/E n/m n/m 8.50
P/S 58.14 16,148.72 9.71
P/B n/m 18.07 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 63.56 15,310.43 9.21
Earnings yield (10.57%) (7.66%) (33.15%)
Free cash flow yield (2.99%) (4.04%) (25.50%)

Profitability

Metric IBRX SMMT Biotechnology median
Gross margin 99.34% 100.00% 65.16%
Operating margin (151.88%) 0.00% 0.00%
Net margin (598.56%) 0.00% 0.00%
Free cash flow margin (173.76%) 0.00% 0.00%
Return on equity 122.85% (192.50%) (56.36%)
Return on assets (192.58%) (159.09%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IBRX SMMT Biotechnology median
Revenue growth (TTM) 192.92% (61.03%) 6.02%
EPS growth (last fiscal year) 38.71% (364.52%) 30.26%
Revenue growth, 5-year CAGR 184.76% (46.49%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IBRX SMMT Biotechnology median
Debt to equity (0.74) 0.00 0.00
Current ratio 5.72 6.96 4.72
Net debt to EBITDA (0.97) 0.65 0.96

Dividend

Metric IBRX SMMT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IBRX SMMT Biotechnology median
Market cap 10.60b 12.26b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack